Evaluation of anticonvulsants for possible use in neuropathic pain

Current Medicinal Chemistry

Volumn 18, Issue 28, 2011, Pages 4344-4358

  Waszkielewicz, A M ^a   Gunia, A ^a   Sloczynska K ^a   Marona, H ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Allodynia; Analgesic; Anticonvulsant; CCI; Epilepsy; Hyperalgesia; Neuropathic pain; Preclinical; Seizures; SNL

Indexed keywords

1 [3 [2,5 BIS(TRIFLUOROMETHYL)PHENYL]PHENYL] 5 METHYLPYRAZOLE 3 CARBOXAMIDE; 2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBONYLUREA; 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; ANTICONVULSIVE AGENT; BRIVARACETAM; CARBAMAZEPINE; CNS 5161; DIISOPROPYLACETAMIDE; DULOXETINE; FENPROPATHRIN; GABAPENTIN; HARKOSERIDE; INDANTADOL; LAMOTRIGINE; LIDOCAINE; N METHYL 2,2,3,3 TETRAMETHYLCYCLOPROPANECARBOXAMIDE; NGX 426; NS 479; OXCARBAZEPINE; PREGABALIN; PYRAZOLE DERIVATIVE; RETIGABINE; TEZAMPANEL; TIAGABINE; TOPIRAMATE; UCBL 059; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALNOCTAMIDE; VALPROIC ACID; VALPROIC ACID DERIVATIVE; VALPROMIDE; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

ABDOMINAL CRAMP; ABNORMAL THINKING; AGGRESSION; ANALGESIC ACTIVITY; ANOREXIA; ANTICONVULSANT ACTIVITY; APLASTIC ANEMIA; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; BALANCE DISORDER; BIRTH DEFECT; BLURRED VISION; COGNITIVE DEFECT; COORDINATION DISORDER; COUGHING; DIARRHEA; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EPIDERMOLYSIS; EPILEPSY; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; IRRITABILITY; LENNOX GASTAUT SYNDROME; LEUKOPENIA; LIVER TOXICITY; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; RASH; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN INFLAMMATION; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; TREATMENT INDICATION; TREMOR; TRIGEMINUS NEURALGIA; VERTIGO; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; WEIGHT REDUCTION; XEROSTOMIA;

ANTICONVULSANTS; EXCITATORY AMINO ACID ANTAGONISTS; GABA-A RECEPTOR ANTAGONISTS; HUMANS; ION CHANNELS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; NEURALGIA;

EID: 80052919231     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797200408     Document Type: Review

References (165)

1. Finnerup, N. B.; Otto, M.; McQuay, H. J.; Jensen, T. S.; Sindrup, S. H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain, 2005, 118, 289-305. (Pubitemid 41752987)
2. Zilliox, L.; Russell, J. W. Treatment of diabetic sensory polyneuropathy. Curr. Treat. Options Neurol., 2011, 13, 143-159.
3. Moore, R. A.; Straube, S.; Wiffen, P. J.; Derry, S.; McQuay, H. J. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst. Rev., 2009, CD007076.
4. Moore, R. A.; Wiffen, P. J.; Derry, S.; McQuay, H. J. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev., 2011, CD007938.
5. Lunn, M. P.; Hughes, R. A.; Wiffen, P. J. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst. Rev., 2009, CD007115.
6. Wiffen, P. J.; Derry, S.; Moore, R. A.; McQuay, H. J. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst. Rev., 2011, CD005451.
7. Challapalli, V.; Tremont-Lukats, I. W.; McNicol, E. D.; Lau, J.; Carr, D. B. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst. Rev., 2005, CD003345.
8. Wiffen, P. J.; Rees, J. Lamotrigine for acute and chronic pain. Cochrane Database Syst. Rev., 2007, CD006044.
9. Eisenberg, E.; McNicol, E.; Carr, D. Opioids for neuropathic pain. Cochrane Database Syst. Rev., 2006, CD006146.
10. White, S. H.; Woodhead, J. H.; Wilcox, K. S.; Kupferberg, H. J.; Wolf, H. H. In: Antiepileptic Drugs, 5th ed.; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E. Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; pp. 36-48.
11. Zimmermann, M. Pathobiology of neuropathic pain. Eur. J. Pharmacol., 2001, 429, 23-37. (Pubitemid 33043979)
12. Costigan, M.; Scholz, J.; Woolf, C. J. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci., 2009, 32, 1-32.
13. Basbaum, A. I.; Bautista, D. M.; Scherrer, G.; Julius, D. Cellular and molecular mechanisms of pain. Cell, 2009, 139, 267-284.
14. Dib-Hajj, S. D.; Black, J. A.; Waxman, S. G. Voltage-gated sodium channels: therapeutic targets for pain. Pain Med., 2009, 10, 1260-1269.
15. Sheets, P. L.; Heers, C.; Stoehr, T.; Cummins, T. R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther., 2008, 326, 89-99. (Pubitemid 351872141)
16. Nelson, M. T.; Todorovic, S. M.; Perez-Reyes, E. The role of T-type calcium channels in epilepsy and pain. Curr. Pharm. Des., 2006, 12, 2189-2197. (Pubitemid 43891394)
17. Schmader, K. E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Pain, 2002, 350-354. (Pubitemid 35291575)
18. Taylor, R. S. Epidemiology of refractory neuropathic pain. Pain Pract., 2006, 6, 22-26. (Pubitemid 43732685)
19. Kim, K. J.; Yoon, Y. W.; Chung, J. M. Comparison of three rodent neuropathic pain models. Exp. Brain Res., 1997, 113, 200-206. (Pubitemid 27090842)
20. Tanabe, M.; Murakami, T.; Ono, H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy. J. Pharmacol. Sci., 2008, 107, 213-220. (Pubitemid 351931022)
21. Wheeler-Aceto, H.; Porreca, F. The rat paw formalin test: comparison of noxious agents. Pain, 1990, 40, 229-238. (Pubitemid 20070791)
22. Bardin, L. In the formalin model of tonic nociceptive pain, 8-OH-DPAT produces 5-HT1A receptor-mediated, behaviorally specific analgesia. Eur. J. Pharmacol., 2001, 421, 109-114. (Pubitemid 32524081)
23. Kuner, R. Central mechanisms of pathological pain. Nat. Med., 2010, 16, 1258-1266.
24. Blackburn-Munro, G.; Erichsen, H. K. Antiepileptics and the treatment of neuropathic pain: evidence from animal models. Curr. Pharm. Des., 2005, 11, 2961-2976. (Pubitemid 41149936)
25. Winkler, I.; Sobol, E.; Yagen, B.; Steinman, A.; Devor, M.; Bialer, M. Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. Neuropharmacol, . 2005, 49, 1110-1120. (Pubitemid 41608635)
26. Bialer, M.; White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov., 2010, 9, 68-82.
27. Zadrozniak, A.; Trojnar, M.; Trojnar, M. Diltiazem enhances the protective activity of oxcarbazepine against maximal electroshock-induced seizures in mice. J. Pre-Clin. Clin. Res., 2008, 2, 147-152.
28. Brodie, M. J.; Dichter, M. A. Antiepileptic Drugs. N. Engl. J. Med., 1996, 3, 168-175.
29. Tomson, T.; Battino, D.; Bonizzoni, E.; Craig, J.; Lindhout, D.; Sabers, A.; Perucca, E.; Vajda, F. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol., 2011, 10, 609-617.
30. Chapman, V.; Suzuki, R.; Chamarette, H. L.; Rygh, L. J.; Dickenson, A. H. Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain, 1998, 75, 261-272. (Pubitemid 28160137)
31. Bianchi, M.; Rossoni, G.; Sacerdote, P.; Panerai, A. E.; Berti, F. Carbamazepine exerts anti-inflammatory effects in the rat. Eur. J. Pharmacol., 1995, 294, 71-74. (Pubitemid 26015036)
32. Backonja, M. M. Use of anticonvulsants for treatment of neuropathic pain. Neurology2002, 59, S14-S17.
33. Carrazana, E. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J. Pain Symptom Manage., 2003, 25, S31-S35. (Pubitemid 36411839)
34. Benes, J.; Parada, A.; Figueiredo, A.; Alves, P. C.; Freitas, A. P.; Learmonth, D. A.; Cunha, R. A.; Garrett, J.; Soares-da-Silva, P. Anticonvulsant and sodium channel-blocking properties of novel 10, 11-dihydro-5H-dibenz[b,f] azepine-5-carboxamide derivatives. J. Med. Chem., 1999, 42, 2582-2587. (Pubitemid 29344298)
35. Jang, Y.; Kim, E S.; Park, S. S.; Lee, J.; Moon, D. E. The suppressive effects of oxcarbazepine on mechanical and cold allodynia in a rat model of neuropathic pain. Anesth. Analg. 2005, 101, 800-806. (Pubitemid 41208514)
36. Fujiwara, Y.; Sato, M.; Otsuki, S. Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacol., 1986, 90, 332-335. (Pubitemid 16022466)
37. Mashimoto, S.; Ushijima, I.; Suetsugi, M.; Akimoto, T.; Watanabe, K.; Yamada, M. Stress-dependent antinociceptive effects of carbamazepine: A study in stressed and nonstressed rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1998, 22, 159-168. (Pubitemid 28096435)
38. Dogra, S.; Beydoun, S.; Mazzola, J.; Hopwood, M.; Wan, Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur. J. Pain, 2005, 9, 543-554. (Pubitemid 41219786)
39. Beydoun, A.; Shaibani, A.; Hopwood, M.; Wan, Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurologica Scandinavica2006, 113, 395-404. (Pubitemid 44046325)
40. Grosskopf, J.; Mazzola, J.; Wan, Y.; Hopwood, M. A randomized, placebocontrolled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol. Scand., 2006, 114, 177-180. (Pubitemid 44185910)
41. Rowley, N. M.; White, H. S. Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: Correlation with other seizure and epilepsy models. Epilepsy Res., 2010, 92, 163-169.
42. Yamashita, H.; Ohno, K.; Amada, Y.; Hattori, H.; Ozawa-Funatsu, Y.; Toya, T.; Inami, H.; Shishikura, J.; Sakamoto, S.; Okada, M. Effects of 2-[N-(4-Chlorophenyl)-N-methylamino]-4H-pyrido[3. 2-e]-1, 3-thiazin-4-one (YM928), an orally active a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats. J. Pharmacol. Exp. Ther., 2004, 308, 127-133. (Pubitemid 38090710)
43. Upton, N.; Blackburn, T. P.; Campbell, C. A.; Cooper, D.; Evans, M. L.; Herdon, H. J.; King, P. D.; Ray, A. M.; Stean, T. O.; Chan, W. N.; Evans, J. M.; Thompson, M. Profile of SB-204269, a mechanistically novel anticonvulsant drug, in rat models of focal and generalized epileptic seizures. Br. J. Pharmacol., 1997, 121, 1679-1686. (Pubitemid 27343396)
44. Lee, S. A.; Lee, H. W.; Heo, K.; Shin, D. J.; Song, H. K.; Kim, O. J.; Lee, S. M.; Kim, S. O.; Lee, B. I. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure, 2011, 20, 49-54.
45. Holmes, G. L.; Frank, L. M.; Sheth, R. D.; Philbrook, B.; Wooten, J. D.; Vuong, A.; Kerls, S.; Hammer, A. E.; Messenheimer, J. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res., 2008, 82, 124-132.
46. Drizin, I.; Gregg, R. J.; Scanio, M. J. C.; Shi, L.; Gross, M. F.; Atkinson, R. N.; Thomas, J. B.; Johnson, M. S.; Carroll, W. A.; Marron, B. E.; Chapman, M. L.; Liu, D.; Krambis, M. J.; Shieh, C. C.; Zhang, X.; Hernandez, G.; Gauvin, D. M.; Mikusa, J. P.; Zhu, C. Z.; Joshi, S.; Honore, P.; Marsh, K. C.; Roeloffs, R.; Werness, S.; Krafte, D. S.; Jarvis, M. F.; Faltynek, C. R.; Kort, M. E. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg. Med. Chem., 2008, 16, 6379-6386. (Pubitemid 351783416)
47. Shaikh, S.; Yaacob, H. B.; Abd Rahman, R. B. Lamotrigine for trigeminal neuralgia: Efficacy and safety in comparison with carbamazepine. J. Chin. Med. Assoc., 2011, 74, 243-249.
48. Eisenberg, E.; Lurie, Y.; Braker, C.; Daoud, D.; Ishay, A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology, 2001, 57, 505-509. (Pubitemid 32757601)
49. Jose, V. M.; Bhansali, A.; Hota, D.; Pandhi, P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet. Med., 2007, 24, 377-383. (Pubitemid 46452398)
50. Rao, R. D.; Flynn, P. J.; Sloan, J. A.; Wong, G. Y.; Novotny, P.; Johnson, D. B.; Gross, H. M.; Renno, S. I.; Nashawaty, M.; Loprinzi, C. L. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer, 2008, 112, 2802-2808. (Pubitemid 351969227)
51. Simpson, D. M.; Olney, R.; McArthur, J. C.; Khan, A.; Godbold, J.; Ebel-Frommer, K. A placebo-controlled trial of lamotrigine for painful HIVassociated neuropath . Neurology, 2000, 54, 2115-2119. (Pubitemid 30397212)
52. Errington, A. C.; Sto, T.; Heers, C.; Lees, G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol., 2008, 73, 157-169. (Pubitemid 350294207)
53. Beyreuther, B. K.; Freitag, J.; Heers, C.; Krebsfänger, N.; Scharfenecker, U.; Stöhr, T. Lacosamide: a review of preclinical properties. CNS Drug Rev., 2007, 13, 21-42. (Pubitemid 46697839)
54. Chen, L. L. K.; Haneef, Z.; Dorsch, A.; Keselman, I.; Stern, J. M. Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. Seizure, 2011, 20, 263-265.
55. Koubeissi, M. Z.; Mayor, C. L.; Estephan, B.; Rashid, S.; Azar, N. J. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol. Scand., 2011, 123, 142-146.
56. Errington, A. C.; Coyne, L.; Stöhr, T.; Selve, N.; Lees, G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacol., 2006, 50, 1016-1029. (Pubitemid 43794912)
57. Beyreuther, B. K.; Callizot, N.; Brot, M. D.; Feldman, R.; Bain, S. C.; Stöhr, T. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur. J. Pharmacol., 2007, 565, 98-104. (Pubitemid 46782774)
58. Bee, L. A.; Dickenson, A. H. Effects of lacosamide, a novel sodium channel modulator, on dorsal horn neuronal responses in a rat model of neuropathy. Neuropharmacol., 2009, 57, 472-479.
59. Hao, J. X.; Stöhr, T.; Selve, N.; Wiesenfeld-Hallin, Z.; Xu, X. J. Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur. J. Pharmacol., 2006, 553, 135-140. (Pubitemid 44779609)
60. Beyreuther, B.; Callizot, N.; Stöhr, T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur. J. Pharmacol., 2006, 539, 64-70. (Pubitemid 43783512)
61. Stöhr, T.; Krause, E.; Selve, N. Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur. J. Pain, 2006, 10, 241-249. (Pubitemid 43255211)
62. Shaibani, A.; Fares, S.; Selam, J. L.; Arslanian, A.; Simpson, J.; Sen, D.; Bongardt, S. Lacosamide in painful diabetic neuropathy: an 18-week doubleblind placebo-controlled trial. J. Pain, 2009, 10, 818-828.
63. Rauck, R. L.; Shaibani, A.; Biton, V.; Simpson, J.; Koch, B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebocontrolled study. Clin. J. Pain, 2007, 23, 150-158. (Pubitemid 46150939)
64. Ziegler, D.; Hidvégi, T.; Gurieva, I.; Bongardt, S.; Freynhagen, R.; Sen, D.; Sommerville, K. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care, 2010, 33, 839-841.
65. Czapiński, P.; Blaszczyk, B.; Czuczwar, S. J. Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem., 2005, 5, 3-14. (Pubitemid 40202106)
66. Baulac, M. Introduction to zonisamide. Epilepsy Res., 2006, 68, S3-S9. (Pubitemid 43247591)
67. Guay, D. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: Potential use in neuropathic pain. Am. J. Geriatr. Pharmacother., 2003, 1, 18-37. (Pubitemid 40410984)
68. Macdonald, R. In: Antiepileptic Drugs, 5th ed.; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds.; Lippincott Williams & Wilkins Healthcare: Philadelphia, 2002; pp. 867-872.
69. Faught, E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure, 13 Suppl 1, S59-S65.
70. Hord, A. H.; Denson, D. D.; Chalfoun, A. G.; Azevedo, M. I. The effect of systemic zonisamide (zonegran) on thermal hyperalgesia and mechanical allodynia in rats with an experimental mononeuropathy. Anesth. Analg., 2003, 1700-1706. (Pubitemid 36623130)
71. Perucca, E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol. Res., 1997, 35, 241-256. (Pubitemid 27331181)
72. Kaminski, R. M.; Banerjee, M.; Rogawski, M. A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacol., 2004, 46, 1097-1104. (Pubitemid 38529933)
73. Bischofs, S.; Zelenka, M.; Sommer, C. Evaluation of topiramate as an antihyperalgesic and neuroprotective agent in the peripheral nervous system. J. Periph. Nerv. Syst., 2004, 9, 70-78. (Pubitemid 38669199)
74. Ormrod, D.; McClellan, K. Topiramate: a review of its use in childhood epilepsy. Paediatr. Drugs, 2001, 3, 293-319. (Pubitemid 32391810)
75. Benoliel, R.; Tal, M.; Eliav, E. Effects of topiramate on the chronic constriction injury model in the rat. J. Pain, 2006, 7, 878-883. (Pubitemid 44854736)
76. Raskin, P.; Donofrio, P. D.; Rosenthal, N. R.; Hewitt, D. J.; Jordan, D. M.; Xiang, J.; Vinik, A. I. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology, 2004, 63, 865-873. (Pubitemid 39297649)
77. Thienel, U.; Neto, W.; Schwabe, S. K.; Vijapurkar, U. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol. Scand., 2004, 110, 221-231. (Pubitemid 39274056)
78. Tyagarajan, S.; Chakravarty, P. K.; Zhou, B.; Taylor, B.; Fisher, M. H.; Wyvratt, M. J.; Lyons, K.; Klatt, T.; Li, X.; Kumar, S.; Williams, B.; Felix, J.; Priest, B. T.; Brochu, R. M.; Warren, V.; Smith, M.; Garcia, M.; Kaczorowski, G. J.; Martin, W. J.; Abbadie, C.; McGowan, E.; Jochnowitz, N.; Parsons, W. H. Substituted biaryl pyrazoles as sodium channel blockers. Bioorg. Med. Chem. Lett., 2010, 20, 5480-5483.
79. Tyagarajan, S.; Chakravarty, P. K.; Zhou, B.; Taylor, B.; Eid, R.; Fisher, M. H.; Parsons, W. H.; Wyvratt, M. J.; Lyons, K.; Klatt, T. Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain. Bioorg. Med. Chem. Lett., 2010, 20, 7479-7482.
80. Omori, Y.; Kagaya, K.; Enomoto, R.; Sasaki, A.; Andoh, T.; Nojima, H.; Takahata, H.; Kuraishi, Y. A mouse model of sural nerve injury-induced neuropathy: gabapentin inhibits pain-related behaviors and the hyperactivity of wide-dynamic range neurons in the dorsal horn. J. Pharmacol. Sci., 2009, 109, 532-539.
81. Bialer, M.; Johannessen, S. I.; Levy, R. H.; Perucca, E.; Tomson, T.; White, H. S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res., 2010, 92, 89-124.
82. Taylor, C. P. In Antiepileptic Drugs, 5th ed.; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; pp. 321-334.
83. Anhut, H.; Ashman, P.; Feuerstein, T. J.; Sauermann, W.; Saunders, M.; Schmidt, B. Gabapentin (neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia, 1994, 35, 795-801. (Pubitemid 24278033)
84. Sivenius, J.; Kälviäinen, R.; Ylinen, A.; Riekkinen, P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia, 1991, 32, 539-542.
85. Appleton, R.; Fichtner, K.; LaMoreaux, L.; Alexander, J.; Halsall, G.; Murray, G.; Garofalo, E. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebocontrolled study. Epilepsia, 1999, 40, 1147-1154. (Pubitemid 29372632)
86. Trudeau, V.; Myers, S.; LaMoreaux, L.; Anhut, H.; Garofalo, E.; Ebersole, J. Gabapentin in naive childhood absence epilepsy: results from two doubleblind, placebo-controlled, multicenter studies. J. Child. Neurol., 1996, 11, 470-475. (Pubitemid 26412201)
87. Hayashida, K. I.; Obata, H.; Nakajima, K.; Eisenach, J. C. Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Anesthesiology, 2008, 109, 1077-1084.
88. Kaufmann, D.; Yagen, B.; Minert, A.; Wlodarczyk, B.; Finnell, R. H.; Schurig, V.; Devor, M.; Bialer, M. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacol., 2010, 58, 1228-1236.
89. Rowbotham, M.; Harden, N.; Stacey, B.; Bernstein, P.; Magnus-Miller, L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA, 1998, 280, 1837-1842. (Pubitemid 28544424)
90. Dooley, D. J.; Mieske, C. A.; Borosky, S. A. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci. Lett., 2000, 280, 107-110. (Pubitemid 30109144)
91. Rosenberg, J. M.; Harrell, C.; Ristic, H.; Werner, R. A.; de Rosayro, A. M. The effect of gabapentin on neuropathic pain. Clin. J. Pain, 1997, 13, 251-255. (Pubitemid 27524085)
92. Rice, A. S. C.; Maton, S. Gabapentin in postherpetic neuralgia: a randomised , double blind, placebo controlled study. Pain, 2001, 94, 215-224. (Pubitemid 33016615)
93. Backonja, M.; Glanzman, R. L. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin. Ther., 2003, 25, 81-104. (Pubitemid 36206739)
94. Chandra, K.; Shafiq, N.; Pandhi, P.; Gupta, S.; Malhotra, S. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized , double-blind clinical trial - the GONIP trial. Int. J. Clin. Pharmacol. Ther., 2006, 44, 358-363. (Pubitemid 44210010)
95. Irving, G.; Jensen, M.; Cramer, M.; Wu, J.; Chiang, Y. K.; Tark, M.; Wallace, M. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia. Clin. J. Pain, 2009, 25, 185-192.
96. Caraceni, A.; Zecca, E.; Bonezzi, C.; Arcuri, E.; Yaya Tur, R.; Maltoni, M.; Visentin, M.; Gorni, G.; Martini, C.; Tirelli, W.; Barbieri, M.; De Conno, F. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J. Clin. Oncol., 2004, 22, 2909-2917. (Pubitemid 41079911)
97. Ross, J. R.; Goller, K.; Hardy, J.; Riley, J.; Broadley, K.; A'Hern, R.; Williams, J. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J. Palliat. Med., 2005, 8, 1118-1126. (Pubitemid 43010543)
98. Sandercock, D.; Cramer, M.; Wu, J.; Chiang, Y. K.; Biton, V.; Heritier, M. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Care2009, 32, e20.
99. Rundfeldt, C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. J. Pharmacol., 1997, 336, 24324-24329.
100. Rundfeldt, C.; Netzer, R. The novel anticonvulsant retigabine activates Mcurrents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. 2000, 282, 73-76. (Pubitemid 30129172)
101. Bialer, M.; Johannessen, S. I.; Kupferberg, H. J.; Levy, R. H.; Loiseau, P.; Perucca, E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res., 1999, 34, 1-41. (Pubitemid 29130316)
102. Blackburn-Munro, G.; Dalby-Brown, W.; Mirza, N. R.; Mikkelsen, J. D.; Blackburn-Munro, R. E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev., 2005, 11, 1-20. (Pubitemid 40577943)
103. Brodie, M. J.; Lerche, H.; Gil-Nagel, A.; Elger, C.; Hall, S.; Shin, P.; Nohria, V.; Mansbach, H. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology, 2010, 75, 1817-1824.
104. Owen, R. T. Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures. Drugs Today, 2010, 46, 815-822.
105. Munro, G.; Erichsen, H. K.; Mirza, N. R. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacol., 2007, 53, 609-618. (Pubitemid 47513167)
106. Blackburn-Munro, G. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharmacol., 2003, 460, 109-116. (Pubitemid 36139977)
107. Zaccara, G.; Gangemi, P.; Perucca, P.; Specchio, L. The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia, 2011, 52, 826-836.
108. Ryvlin, P.; Kälviäinen, R.; Von Raison, F.; Giordano, S.; Emir, B.; Chatamra, K. Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS). Eur. J. Neurol., 2010, 17, 726-732.
109. Mantoan, L.; Walker, M. Treatment options in juvenile myoclonic epilepsy. Curr. Treat. Options Neurol., 2011, 13, 1-16.
110. Field, M. J.; Bramwell, S.; Hughes, J.; Singh, L. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? Pain, 1999, 83, 303-311. (Pubitemid 29479290)
111. Rosenstock, J.; Tuchman, M.; Lamoreaux, L.; Sharma, U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind , placebocontrolled trial. Pain, 2004, 110, 628-638. (Pubitemid 39036794)
112. van Seventer, R.; Feister, H. A.; Young, J. P. J.; Stroker, M.; Versavel, M.; Rigaudy, L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr. Med. Res. Opin., 2006, 22, 375-384. (Pubitemid 44296762)
113. Satoh, J.; Yagihashi, S.; Baba, M.; Suzuki, M.; Arakawa, A.; Yoshiyama, T.; Shoji, S. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, doubleblind, placebo-controlled trial. Diabet. Med., 2011, 28, 109-116.
114. Tölle, T.; Freynhagen, R.; Versavel, M.; Trostmann, U.; Young, J. P. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur. J. Pain, 2008, 12, 203-213. (Pubitemid 350180540)
115. Arezzo, J. C.; Rosenstock, J.; Lamoreaux, L.; Pauer, L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurology, 2008, 8, 33-46.
116. Moon, D. E.; Lee, D. I.; Lee, S. C.; Song, S. O.; Yoon, D. M.; Yoon, M. H.; Kim, H. K.; Lee, Y. W.; Kim, C.; Lee, P. B. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebocontrolled, multicenter study. Clin. Ther., 2010, 32, 2370-2385.
117. Guan, Y.; Ding, X.; Cheng, Y.; Fan, D.; Tan, L.; Wang, Y.; Zhao, Z.; Hong, Z.; Zhou, D.; Pan, X.; Chen, S.; Martin, A.; Tang, H.; Cui, L. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexibledose, double-blind, placebo-controlled study conducted in China. Clin. Ther., 2011, 33, 159-166.
118. Semel, D.; Murphy, T. K.; Zlateva, G.; Cheung, R.; Emir, B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam. Pract., 2010, 11, 85-97.
119. Johannessen, C. U. Mechanisms of action of valproate: a commentatory. Neurochem. Int., 2000, 37, 103-110. (Pubitemid 30254142)
120. Löscher, W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drug, s2002, 16, 669-694. (Pubitemid 35176853)
121. Shimshoni, J. A.; Bialer, M.; Wlodarczyk, B.; Finnell, R. H.; Yagen, B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J. Med. Chem., 2007, 50, 6419-6427. (Pubitemid 350250429)
122. Kochar, D. K.; Rawat, N.; Agrawal, R. P.; Vyas, A.; Beniwal, R.; Kochar, S. K.; Garg, P. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM, 2004, 97, 33-38. (Pubitemid 38195700)
123. Kochar, D. K.; Jain, N.; Agarwal, R. P.; Srivastava, T.; Agarwal, P.; Gupta, S. Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Acta Neurol. Scand., 2002, 106, 248-252. (Pubitemid 35177990)
124. Otto, M.; Bach, F. W.; Jensen, T. S.; Sindrup, S. H. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology, 2004, 62, 285-288. (Pubitemid 38167141)
125. Winkler, I.; Blotnik, S.; Shimshoni, J.; Yagen, B.; Devor, M.; Bialer, M. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol., 2005, 146, 198-208. (Pubitemid 43079959)
126. Isoherranen, N.; Woodhead, J. H.; White, H. S.; Bialer, M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia, 2001, 42, 831-836. (Pubitemid 32783089)
127. Kaufmann, D.; Yagen, B.; Minert, A.; Tal, M.; Devor, M.; Bialer, M. Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacol., 2008, 54, 699-707.
128. Spiegelstein, O.; Yagen, B.; Levy, R. H.; Finnell, R. H.; Bennett, G. D.; Roeder, M.; Schurig, V.; Bialer, M. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm. Res., 1999, 16, 1582-1588. (Pubitemid 29510556)
129. Kaufmann, D.; Bialer, M.; Shimshoni, J. A.; Devor, M.; Yagen, B. Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. J. Med. Chem., 2009, 52, 7236-7248.
130. Fink-Jensen, A.; Suzdak, P. D.; Swedberg, M. D.; Judge, M. E.; Hansen, L.; Nielsen, P. G. The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur. J. Pharmacol., 1992, 220, 197-201.
131. Jedrzejczak, J. Tiagabine as add-on therapy may be more effective with valproic acid - open label , multicentre study of patients with focal epilepsy. Eur. J. Neurol., 2005, 12, 176-180. (Pubitemid 40278523)
132. McKee, P. Treating refractory epilepsy with tiagabine: clinical experience. Seizure, 2004, 13, 478-480.
133. Giardina, W. J.; Decker, M. W.; Porsolt, R. D.; Roux, S.; Collins, S. D.; Kim, D. J. B.; Bannon, A. W. An evaluation of the GABA uptake blocker tiagabine in animal models of neuropathic and nociceptive pain. Drug Dev. Res., 1998, 44, 106-113. (Pubitemid 28452882)
134. James Willmore, L.; Abelson, M. B.; Ben-Menachem, E.; Pellock, J. M.; Donald Shields, W. Vigabatrin: 2008 update. Epilepsia, 2009, 50, 163-173.
135. Alves, N. D.; de Castro-Costa, C. M.; de Carvalho, A. M.; Santos, F. J.; Silveira, D. G. Possible analgesic effect of vigabatrin in animal experimental chronic neuropathic pain. Arq. Neuropsiquiatr., 1999, 57, 916-920.
136. Luszczki, J. J.; Czuczwar, S. J. Dose-response relationship analysis of vigabatrin doses and their antinociceptive effects in the hot-plate test in mice. Pharmacol. Rep., 2008, 60, 409-414.
137. Fuks, B.; Gillard, M.; Michel, P.; Lynch, B.; Vertongen, P.; Leprince, P.; Klitgaard, H.; Chatelain, P. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol., 2003, 478, 11-19. (Pubitemid 38366069)
138. Lambeng, N.; Gillard, M.; Vertongen, P.; Fuks, B.; Chatelain, P. Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord. Eur. J. Pharmacol., 2005, 520, 70-76. (Pubitemid 41375813)
139. Klitgaard, H.; Matagne, A.; Gobert, J.; Wülfert, E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol., 1998, 353, 191-206. (Pubitemid 28352266)
140. Ardid, D.; Lamberty, Y.; Alloui, A.; Coudore-Civiale, M A.; Klitgaard, H.; Eschalier, A. Antihyperalgesic effect of levetiracetam in neuropathic pain models in rats. Eur. J. Pharmacol., 2003, 473, 27-33. (Pubitemid 36851625)
141. Vilholm, O. J.; Cold, S.; Rasmussen, L.; Sindrup, S. H. Effect of levetiracetam on the postmastectomy pain syndrome. Eur. J. Neurol., 2008, 15, 851-857.
142. Holbech, J. V.; Otto, M.; Bach, F. W.; Jensen, T. S.; Sindrup, S. H. The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. Eur. J. Pain, 2011, 15, 608-614.
143. Finnerup, N. B.; Grydehøj, J.; Bing, J.; Johannesen, I. L.; Biering-Sørensen, F.; Sindrup, S. H.; Jensen, T. S. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord, 2009, 47, 861-867.
144. Rogawski, M. A.; Bazil, C. W. New molecular targets for antiepileptic drugs: α2δ, SV2A, and Kv7/KCNQ/M potassium channels. Curr. Neurol. Neurosci. Rep., 2008, 8, 345-352.
145. Schulze-Bonhage, A. Brivaracetam for the treatment of epilepsy. Expert Opin. on Pharmacother., 2011, [Epub ahead of print].
146. A study assessing efficacy of brivaracetam in subjects with persistent pain after shingles (post-herpetic neuralgia). http://clinicaltrials.gov/ct2/ show/NCT00160667?term=brivaracetam&rank=8 (Accessed July 14, 2011).
147. Parsons, C. G. NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol., 2001, 429, 71-78. (Pubitemid 33043983)
148. Garry, E. Specific involvement in neuropathic pain of AMPA receptors and adapter proteins for the GluR2 subunit. Mol. Cell. Neurosci., 2003, 24, 10-22. (Pubitemid 37203443)
149. Walters, M. R.; Bradford, A. P. J.; Fischer, J.; Lees, K. R. Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br. J. Clin. Pharmacol., 2002, 53, 305-311. (Pubitemid 34226973)
150. Hu, L. Y.; Guo, J.; Magar, S. S.; Fischer, J. B.; Burke-Howie, K. J.; Durant, G. J. Synthesis and pharmacological evaluation of N-(2, 5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-Daspartate receptor ion-channel blockers. J. Med. Chem., 1997, 40, 4281-4289. (Pubitemid 28042307)
151. Forst, T.; Smith, T.; Schütte, K.; Marcus, P.; Pfützner, A. Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain. Br. J. Clin. Pharmacol., 2007, 64, 75-82. (Pubitemid 46934426)
152. Danysz, W.; Parsons, C. G. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox. Res., 2002, 4, 119-126. (Pubitemid 34285054)
153. Nielsen, E. O.; Varming, T.; Mathiesen, C.; Jensen, L. H.; Moller, A.; Gouliaev, A. H.; Wätjen, F.; Drejer, J. SPD 502: a water-soluble and in vivo longlasting AMPA antagonist with neuroprotective activity. J. Pharmacol. Exp. Ther., 1999, 289, 1492-1501. (Pubitemid 29246682)
154. Pitkänen, A.; Mathiesen, C.; Rønn, L. C. B.; Møller, A.; Nissinen, J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res., 2007, 74, 45-54. (Pubitemid 46413707)
155. Blackburn-Munro, G.; Bomholt, S. F.; Erichsen, H. K. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain. Neuropharmacol., 2004, 47, 351-362. (Pubitemid 38953226)
156. Gormsen, L.; Finnerup, N. B.; Almqvist, P. M.; Jensen, T S. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth. Analg., 2009, 108, 1311-1319.
157. Mattia, C.; Coluzzi, F. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs, 2007, 10, 636-644. (Pubitemid 47360927)
158. Bassani, F.; Bergamaschi, M.; Tonino Bolzoni, P.; Villetti, G. CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. Eur. J. Pharmacol., 2005, 519, 231-236. (Pubitemid 41278543)
159. Villetti, G.; Bergamaschi, M.; Bassani, F.; Bolzoni, P. T.; Maiorino, M.; Pietra, C.; Rondelli, I.; Chamiot-Clerc, P.; Simonato, M.; Barbieri, M. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther., 2003, 306, 804-814. (Pubitemid 36886183)
160. Villetti, G.; Bregola, G.; Bassani, F.; Bergamaschi, M.; Rondelli, I.; Pietra, C.; Simonato, M. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacol., 2001, 40, 866-878. (Pubitemid 32510800)
161. Study of the safety, tolerability and efficacy of V3381 in patients with diabetic peripheral neuropathic pain. http://clinicaltrials. gov/ct2/show/NCT00794430 (Accessed July 15, 2011).
162. Rogawski, M. A.; Kurzman, P. S.; Yamaguchi, S.; Li, H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdale kindling in the mouse. Neuropharmacol., 2000, 40, 28-35. (Pubitemid 33779797)
163. Sang, C. N.; Hostetter, M. P.; Gracely, R. H.; Chappell, A. S.; Schoepp, D. D.; Lee, G.; Whitcup, S.; Caruso, R.; Max, M. B. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology, 1998, 89, 1060-1067. (Pubitemid 28516529)
164. Perucca, E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia, 2009, 50 Suppl 1, 49-50.
165. Gustafsson, H.; Sandin, J. Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain. Eur. J. Pharmacol., 2009, 605, 103-108.